A5050995200- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- Healthcare Systems and Practices
- Viral-associated cancers and disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research
- Hepatitis C virus research
- Lymphoma Diagnosis and Treatment
- HIV/AIDS oral health manifestations
- Medication Adherence and Compliance
- Mobile Health and mHealth Applications
- Migration, Identity, and Health
- Polyomavirus and related diseases
- Health Literacy and Information Accessibility
- Pharmaceutical Economics and Policy
- Oral Health Pathology and Treatment
- Systemic Lupus Erythematosus Research
- Oral and gingival health research
- Toxoplasma gondii Research Studies
- Neurological Complications and Syndromes
- Health, Medicine and Society
- Immune Cell Function and Interaction
Centre Hospitalier Universitaire de Clermont-Ferrand
2015-2025
Inserm
1995-2024
Assistance Publique – Hôpitaux de Paris
2007-2024
Université Paris-Saclay
1995-2024
Centre de recherche en Epidémiologie et Santé des Populations
2024
Hôpitaux Universitaires Paris-Ouest
2024
Université Paris Cité
2007-2023
Université Clermont Auvergne
2023
Medical University of Vienna
2022
Centre Hospitalier Universitaire de Martinique
2018-2021
Assessment of the risks transmission infection with human immunodeficiency virus type 1 (HIV-1) from mother to newborn is difficult, partly because persistence for up a year maternal antibodies transmitted passively infant. To determine frequency perinatal HIV infection, we studied birth 308 infants born seropositive women, 62 percent whom were intravenous drug abusers. Of 117 evaluated 18 months after birth, 32 (27 percent) or had died acquired syndrome (AIDS) (n = 6); 32, only 2 remained...
The introduction of 2 or 3 fully active drugs in human immunodeficiency virus (HIV)-infected patients receiving failing antiretroviral therapy is a key determinant subsequent treatment efficacy. aim this study was to assess the safety and efficacy regimen containing raltegravir, etravirine, darunavir/ritonavir for treatment-experienced infected with multidrug-resistant HIV.Patients enrolled phase II, noncomparative, multicenter trial were naive investigational had plasma HIV RNA levels >1000...
Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD). However, most patients, cannot be discontinued.To evaluate the efficacy of four weekly rituximab infusions (375 mg/m(2)) after discontinuation MCD, 24 patients were enrolled onto a prospective open-label trial.At study entry, median time from MCD diagnosis was 21 months. All had stable on and dependent for 13 The CD4 cell count 270 x 10(6)/L, plasma HIV RNA less than 50 copies/mL 18...
Background The occurrence of viral control after interruption an antiretroviral treatment (ART) initiated during primary HIV-1 infection (PHI) is rare and the frequency predictive factors such a are unknown. Methods Within French ANRS PRIMO Cohort, 164 patients interrupted ART PHI. We compared whose load (VL) remained undetectable (<50 copies/ml) or low (50–500 1 year to those who evidenced rapid rebound. Results After interruption, VL for median time 4.5 years in 14 (‘post-ART...
ABSTRACT Proviral human immunodeficiency virus type 1 (HIV-1) DNA could be a useful marker for exploring viral reservoirs and monitoring antiretroviral treatment, particularly when HIV-1 RNA is undetectable in plasma. A new technique was developed to quantify proviral using TaqMan real-time PCR assay. One copy of detected with 100% sensitivity five copies the assay had range 6 log 10 . Reproducibility evaluated intra- interassays independent extractions 8E5 cell line harboring genome...
A polymerase chain reaction (PCR)-based method was used to detect cytomegalovirus (CMV) DNA in 82 cerebrospinal fluid (CSF) samples from 67 patients infected by human immunodeficiency virus (HIV). The test positive for 14 patients, 8 of whom had CMV-related neurologic disease proven viral culture CSF or histologic examination. Encephalitis the most frequent manifestation with PCR results, but CMV also present some peripheral neuropathy polyradiculomyelitis. All were PCR. In contrast,...
Background Self-stigmatization is the process by which environmental stigmas are internalized. It leads to a decline in self-esteem, isolation, denial and risk behavior, impairs quality of life. The aims our study were investigate psychological, social medical factors, particular psychological flexibility its defusion component, that associated with resilience self-stigmatization people living HIV (PLHIV), assess clinicians’ perceptions condition. Methods A multicenter observational was...
Abstract Background Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at time primary HIV-1 infection (PHI) in 2007–12. Methods resistance-associated mutations (RAMs) were characterized using both 2009 WHO list and ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination. Results Patients mainly MSM (72.6%). Non-B variants identified 33.7% patients. The proportion TDR as 11.7%...
To analyse the frequency and causes of treatment discontinuation in patients who were treated with an integrase strand transfer inhibitor (INSTI), a focus on neuropsychiatric adverse events (NPAEs). Patients 18 HIV reference centres France prospectively included Dat'AIDS cohort. Data collected from all starting INSTI-containing regimen between 1 January 2006 31 December 2016. All discontinuations analysed, patients' characteristics related to due NPAEs sought. INSTIs prescribed 21315...
Abstract Epstein‐Barr virus (EBV) reactivation is more likely to occur in immunocompromised patients with subsequent higher susceptibility EBV‐associated lymphoproliferations. In contrast transplant recipients, limited data are available concerning the EBV load HIV‐infected patients, or without AIDS‐related non‐Hodgkin's lymphomas. We developed a TaqMan real‐time PCR assay, allowing both genome and cellular gene be quantified order obtain reliable normalized measurement of peripheral blood...
Cancer risk is higher in people living with HIV (PLWH) compared the general population, and cancers related to age are expected be most prevalent.We determined spectrum incidence rates of AIDS-defining (ADC) non-AIDS-defining (NADC) lung, Hodgkin lymphoma (HL), head neck (HNC), colon-rectum, anal, liver, breast, prostate, urinary bladder between January 2010 December 2015 French Dat'AIDS cohort. Incidence were calculated by year using χ2 test for linear trend. Standardized ratios [SIR (95%...
Abstract HIV-1 post-treatment controllers are rare individuals controlling infection for years after antiretroviral therapy interruption. Identification of immune correlates control in could aid designing effective vaccine and remission strategies. Here, we perform comprehensive immunoprofiling the humoral response to long-term controllers. Global multivariate analyses combining clinico-virological data reveal distinct profiles experiencing transient viremic episodes off compared those...
In the search for control of human immunodeficiency virus type 1 (HIV-1) infection without antiretroviral therapy, posttreatment controllers (PTCs) are models HIV remission. To better understand their mechanisms control, we characterized blood reservoirs 8 PTCs (median 9.4 years after treatment interruption) in comparison with those 13 natural (HICs) 18 infection) and individuals receiving efficient therapy initiated during either primary (PHIs; n = 8) or chronic (CHIs; 6). This...
Thrombotic microangiopathy (TMA) can occur during the course of human immunodeficiency virus (HIV) infection. Clinical and pathological data for 29 patients with TMA HIV infection were recorded. In a retrospective case-control study, we analyzed link between opportunistic infections or drug therapies TMA. Twenty-five (mean CD4+ cell count + SD, 71.9 18.3/mm3) had renal impairment, four neurological dysfunction. one-half cases, disease was progressive isolated fragmentation anemia appearing...
Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated extended follow-up continued study treatment until week 96. them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at At 96, 88% achieved durable virologic response (<50 copies/mL). CD4 was maintained (median change of +150...
Background In the interest of cost effectiveness, switching antiretroviral brand name medications to generics is recommended in France since 2013. The study objective was evaluate perception per se and HIV-infected patients their hospital physicians Methods Findings 556 out 703 (79%) adult HIV+ outpatients 116 33 clinics were included a multicentric cross-sectional survey performed September Patients completed self-questionnaire on acceptability generics. Physicians questionnaire generic....
Objective: To study the predictive value of clinical criteria and polymerase chain reaction (PCR) assay cerebrospinal fluid (CSF) for diagnosis cytomegalovirus (CMV)-related neurological disorders during AIDS. Setting: Four infectious diseases departments in two tertiary referral teaching hospitals Paris, France. Design participants: One-year prospective involving 164 consecutive immunosuppressed HIV-seropositive patients undergoing lumbar puncture (LP). Methods: A tentative diagnostic...
Since January 1986,51 obstetric and pediatric centers in France have been involved studies of infants born to mothers seropositive for HIV-1. All entering the program were known be classed according criteria CDC. Obstetricians determined mode delivery, breast feeding was discouraged, infant gestational ages assessed by both physical laboratory methods. After birth, size determined, abnormalities recorded (adenopathy, splenomegaly, neurologic signs), examined every two months first year 6...
ABSTRACT We report a rare case of acute human immunodeficiency virus (HIV) type 1 group O infection in French Caucasian woman. Her sexual partner was secondarily diagnosed with HIV infection, and transmission confirmed by phylogenetic analysis. The unequal performance many the serologic molecular assays commercially available leads to delays diagnosis affects patient management.
Kaposi sarcoma is still observed among people living with HIV (PLHIV) including those on ART undetectable viral load (HIV-VL). We aimed to assess incidence and trends between 2010 2015 in France highlight associated factors.Retrospective study using longitudinal data from the Dat'AIDS cohort 44 642 PLWH. For assessment, cases occurring within 30 days of enrollment were excluded.Demographic, immunological, therapeutic characteristics collected at time diagnosis or last visit for patients...
Objectives: ANRS 139 TRIO trial was a phase II noncomparative that evaluated in highly experienced patients, combination of raltegravir, etravirine and darunavir boosted with ritonavir. We analyzed emergence resistant viruses at the time virological failure investigated impact baseline integrase polymorphisms on occurrence. Methods: Bulk sequencing protease, reverse transcriptase genes performed for 103 patients 14 failure. Additionally, clonal analyses were successful gene amplification....
There is a general consensus on the need to start antiretroviral therapy rapidly after diagnosis of HIV infection, although optimal drug combinations and duration treatment are unknown [1]. We treated nine patients with HIV-1 subtype B primary infection triple nucleoside analogue combination (zidovudine, didanosine lamivudine) for 12 months, examined effect discontinuation. Treatment was resumed when plasma viral load reached 20 000 copies/ml. A marked decrease in RNA observed initiation....
The aging population of people living with human immunodeficiency virus (HIV) (PLWH) is exposed to a widening spectrum non-AIDS-defining diseases. Thus, our objective was compare the health care offered PLWH according age. We conducted multicenter cross-sectional study on who consulted at one 59 French HIV reference centers from 15th 19th October 2012. Using survey questionnaires, self-reported medical they received, whether or not tied infection monitoring, during previous year. A total 650...